Bromperidol decanoate (depot) for schizophrenia

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Antipsychotic medications are primary treatments for schizophrenia.
• Long-acting injectable antipsychotics, like bromperidol decanoate, are crucial for long-term schizophrenia management.

Purpose of the Study:

• To evaluate depot bromperidol against placebo, oral antipsychotics, and other depot antipsychotics.
• To assess clinical, social, and economic outcomes in schizophrenia patients.

Main Methods:

• Searched the Cochrane Schizophrenia Group's Register for randomized trials up to February 2011.
• Included trials comparing depot bromperidol with placebo, oral antipsychotics, or other depot preparations.
• Analyzed primary outcomes including global function, service utilization, and relapse rates.

Main Results:

• Four randomized controlled trials (RCTs) with 117 participants were included.
• Bromperidol decanoate showed no significant difference from placebo in adverse effects or study completion.
• Fewer relapses were observed with fluphenazine decanoate and haloperidol decanoate compared to bromperidol decanoate.
• Patients receiving bromperidol decanoate were more likely to discontinue treatment and required additional antipsychotic medication more frequently than those on other depots.

Conclusions:

• Limited trial data suggests bromperidol decanoate may be superior to placebo but inferior to fluphenazine or haloperidol decanoate for schizophrenia.
• Bromperidol decanoate could be a viable option if other depots are contraindicated.
• High-quality, well-reported randomized trials are necessary to guide clinical practice.